(Borneol + edaravone) is a small molecule commercialized by Simcere Pharmaceutical Group, with a leading Phase I program in Acute Ischemic Stroke. According to Globaldata, it is involved in 17 clinical trials, of which 8 were completed, 7 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of (Borneol + edaravone)’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for (Borneol + edaravone) is expected to reach an annual total of $8 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
(Borneol + edaravone) Overview
Dexborneol and Edaravone (Sanbexin) is a fixed dose combination product, acts as a cerebro protective agent. Sanbexin is indicated for the improvement of neurological symptoms and dysfunction of activities of daily living caused by acute cerebral infarction. It is under development for the treatment of acute ischemic stroke, amyotrophic lateral sclerosis and Intracerebral hemorrhage. It acts by targeting free radical. The drug candidate is administered through sublingual route as a tablet and through parenteral route.
See Also:
Simcere Pharmaceutical Group Overview
Simcere Pharmaceutical Group (Simcere) is a pharmaceutical company that discovers, develops, and markets branded generic and prescription pharmaceutical products. The company offers services in therapeutic areas such as anti-tumor, anti-infection, central nervous, cardiovascular, skeletal muscle and others. Simcere’s products are used for the treatment of oncology, infectious diseases, neurology, anti-inflammation and also cardiovascular diseases. The company conducts research and development focused on low-end generics and APIs for innovative medicines. Simcere is headquartered in Nanjing, Jiangsu, China
The company reported revenues of (Renminbi) CNY6,319.1 million for the fiscal year ended December 2022 (FY2022), an increase of 26.4% over FY2021. In FY2022, the company’s operating margin was 13.6%, compared to an operating margin of 29% in FY2021. In FY2022, the company recorded a net margin of 14.8%, compared to a net margin of 30.1% in FY2021.
For a complete picture of (Borneol + edaravone)’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
